## Verkazia (cyclosporine 0.1%) Prior Authorization Request Form

Caterpillar Prescription Drug Benefit Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S LAST NAME:		MEMBER'S FIRST NAME:	
	chart notes or lab data, to su	y and legibly. Attach any additi pport the authorization reques	
			URGENT
MEMBER INFORMATION			
LAST NAME:		FIRST NAME:	
PHONE NUMBER:		DATE OF BIRTH:	
STREET ADDRESS:			
CITY:		STATE: ZIP CODE:	
PATIENT INSURANCE ID NUM	/IBER:		
IF YOU ARE NOT THE PATIENT OR THE PRESCRIF FOLLOWING LINK: PRIMETHERAPEUTICS.COM,  PATIENT'S AUTHORIZED REPR	BER, YOU WILL NEED TO SUBMIT A PHI DISCLUNOPP	HT (LB/KG): ALLERGI OSURE AUTHORIZATION FORM WITH THIS REQI	UEST WHICH CAN BE FOUND AT THE
PRESCRIBER INFORMATION			
LAST NAME:		FIRST NAME:	
PRESCRIBER SPECIALTY:		EMAIL ADDRESS:	
NPI NUMBER:		DEA NUMBER:	
PHONE NUMBER:		FAX NUMBER:	
STREET ADDRESS:			
CITY:		STATE: ZIP CODE:	
REQUESTOR (if different than prescriber):		OFFICE CONTACT PERSON:	
MEDICATION OR MEDICAL I	DISPENSING INFORMATION		
MEDICATION NAME:			
DOSE/STRENGTH:	FREQUENCY:	LENGTH OF THERAPY/REFILLS:	QUANTITY:
NEW THERAPY DURATION OF THERAPY (SPE	RENEWAL CIFIC DATES):	IF RENEWAL: DATE THERAPY	INITIATED:

Continued on next page



## Verkazia (cyclosporine 0.1%) Prior Authorization Request Form

Caterpillar Prescription Drug Benefit Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S LAST NAME:	MEMBER'S FIRST	NAME:
1. HAS THE PATIENT TRIED ANY OTHE	R MEDICATIONS FOR THIS CONDITION?	YES (if yes, complete below) NO
MEDICATION/THERAPY (SPECIFY	<b>DURATION OF THERAPY</b> (SPECIFY	RESPONSE/REASON FOR
DRUG NAME AND DOSAGE):	DATES):	FAILURE/ALLERGY:
2. LIST DIAGNOSES:		ICD-10:
□ Vernal keratoconjunctivitis(VKC)		
☐ Other diagnosis:ICD	-10	
<b>3. REQUIRED CLINICAL INFORMATION</b> PRIOR AUTHORIZATION.	: PLEASE PROVIDE ALL RELEVANT CLINIC	AL INFORMATION TO SUPPORT A
Clinical Information:		
	atient as part of a treatment regimen sp	ecified within a sponsored clinical
trial?   Yes   No	No	
Is prescriber an ophthalmologist?   Y	es 🗆 NO	
For initial requests:		
Does patient have a diagnosis of vern	al keratoconjunctivitis(VKC)? 🗆 Yes 🛭 🗅	10
Does notiont have active severe verns	N koratosoniunstivitis(VVC) sonsistant v	with grade 2 or 4 of Ponini scale with
1 · · · · · · · · · · · · · · · · · · ·	al keratoconjunctivitis(VKC) consistent voor odified Oxford scale?   Yes   No Pleas	_
Does patient have a mean score of 4 s	subjective symptoms(photophobia, tear	ring, itching, and mucous discharge)
greater than or equal to 60mm using	a 100mm Visual Analogue Scale(where	0 means no symptoms and 100 means
the worst that have been ever experie	enced)?   Yes   No Please submit doc	umentation.
Does natient does have any other ocu	llar anomaly other than VKC interfering	with the ocular surface including but
	keratitis, severe blepharitis, rosacea, co	<del>_</del>
	•	
-	my, abnormalities of the nasolacrimal on, or history of ocular varicella-zoster in	
Has patient tried at least 2 of the followard of the foll	owing treatments?   Yes   No Please s	submit documentation.
□ Ophthalmic steroids		
☐ Ophthalmic mast stabilizer		
1		



## Verkazia (cyclosporine 0.1%) Prior Authorization Request Form

Caterpillar Prescription Drug Benefit Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S LAST NAME:	MEMBER'S FIRST NAME:
•	conjunctivitis(VKC) consistent with grade 3 or 4 of Bonini scale with Oxford scale?   No Please submit documentation.
	e symptoms(photophobia, tearing, itching, and mucous discharge)  Note of the value of the symptoms and 100 means  Yes of the Note of the value of the symptoms and 100 means of the value o
Are there any other comments, diagnoses, syr physician feels is important to this review?	mptoms, medications tried or failed, and/or any other information the
<b>Please note:</b> Not all drugs/diagnosis are covere information is received.	ed on all plans. This request may be denied unless all required
ATTESTATION: I attest the information provide	ed is true and accurate to the best of my knowledge. I understand that
the Health Plan, insurer, Medical Group or its d	lesignees may perform a routine audit and request the medical
information necessary to verify the accuracy of	the information reported on this form.
Prescriber Signature or Electronic I.D. Verificat	tion: Date:
you are not the intended recipient, you are hereby notifie	g this transmission contain confidential health information that is legally privileged. If ed that any disclosure, copying, distribution, or action taken in reliance on the contents lived this information in error, please notify the sender immediately (via return FAX) ents.

**FAX THIS FORM TO: 800-424-7640** 

MAIL REQUESTS TO: Prime Therapeutics Management Prior Authorization Program
Attn: CP - 4201
P.O. Box 64811
St. Paul, MN 55164-0811

